Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. It focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

Special Meeting Adjourned to Thursday, November 21, 2024  WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.

Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals

WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024.

Yield10 Bioscience Announces Second Quarter 2024 Financial Results

WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding (“MOU”) and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina.

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina

- EPA approved an amendment to the label of INTERLINE herbicideto include Camelina -The supplemental label now allows application of INTERLINE for over-the-top weed control in Camelina WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that UPL Ltd.

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label

-Earns $1 million in milestone payments from Vision Bioenergy Oilseeds -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds

Yield10 Bioscience Announces First Quarter 2024 Financial Results

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder's equity of at least $2,500,000. Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on May 16, 2024.

Yield10 Bioscience Announces Delisting from Nasdaq

G1 Therapeutics

Biotech stocks are a tricky bunch, prone to wild moves and technical patterns that are tough to nail down.

2 Biotech Stocks to Watch Under $20

WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on Thursday, May 2, 2024, and the Company's common stock will begin trading on a split-adjusted basis on Friday, May 3, 2024.

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split

Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript

-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada -Management will host a conference call today at 4:30 p.m. (ET) to review  financial results and provide a corporate update

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024.

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) recently reviewed information on the Company's E3902 Camelina sativa (“Camelina”) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. Yield10's E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Thursday after the agricultural bioscience company got new approval from the Department of Agriculture's (USDA) Biotechnology Regulatory Services (BRS). The big news here is Yield10 Bioscience's Camelina sativa varieties getting approval for breeding and growth in the U.S. This came after the agency determined the genetically modified plants don't fall under regulations 7 CFR part 340.

Why Is Yield10 (YTEN) Stock Up 117% Today?

Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States.

USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States

-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets -Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update on Nasdaq Status - WOBURN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today provided an update on its Omega-3 Camelina program.

Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program

Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Monday despite a lack of news from the U.S. agricultural bioscience company. This rally comes alongside heavy trading of YTEN stock on Monday morning.

Why Is Yield10 Bioscience (YTEN) Stock Up 34% Today?

WOBURN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company recently filed a request for a Regulatory Status Review (“RSR”) with USDA-APHIS Biotechnology Regulatory Services (“BRS”) under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule for proprietary elite Camelina sativa ("Camelina”) varieties designed to produce seed oil containing both essential omega-3 fatty acids eicosapentaenoic acid (“EPA”) and docosahexaenoic acid (“DHA”).

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America

USDA-APHIS Determines that Yield10 Bioscience's Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

-Yield10 Achieves a Significant Milestone in the Development  of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils

USDA-APHIS Determines that Yield10 Bioscience's Glufosinate Tolerant Camelina May Be Planted and Bred in the United States

Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Lynne Brum - Investor Relations Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice President, Research and Chief Science Officer Chuck Haaser - Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Noel Parks - Tuohy Brothers Operator Hello and welcome to the Third Quarter 2023 Financial Results and Business Update Conference Call for Yield10 Bioscience. [Operator Instructions] As a reminder, this conference call is being recorded.

Yield10 Bioscience, Inc. (YTEN) Q3 2023 Earnings Call Transcript

-Establishes "Camelina Seed Genetics to Biofuel" Platform -Advances Herbicide Tolerant Camelina Varieties toward Commercialization -Exercises Option to Finalize Exclusive, Global Commercial License to Advanced Omega-3 Technology -Management will host a conference call today at 4:30 pm (ET)

Yield10 Bioscience Announces Third Quarter 2023 Financial Results

WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023.

News for Yield10 Bioscience Stock (YTEN)